Sorrento Therapeutics (SRNE) has taken a unique approach to fighting the coronavirus. While most pharma companies taking the good fight to COVID-19 have focused their energies on one area, Sorrento has taken a more scatter gun approach. The biotech is developing a COVID-19 vaccine, a diagnostic test, an antibody test and has several therapeutic candidates.While it remains to be seen whether the varied method pays off, Dawson James analyst Jason Kolbert believes Sorrento might have a fan, who as they say, has some influence in high places.During a presidential press conference, “the president mentioned among promising therapeutics a monoclonal-antibody that …read more
Source:: Yahoo Finance
